ME
Mesoblast Limited
MESO · NASDAQ
$17.32 +1.64% (+$0.28)
1M +3.84%
Market Cap $2.25B
P/E Ratio -
Div. Yield -
ROE 9.98%
Piotroski F-Score Moderate
4/9Valuation
26 /100
Expensive P/B 3.95x
P/S 18.60x
EV/FFO N/A
Growth
88 /100
Growing Book val. growth 4.24%
Rev. growth 152.52%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 42.64%
Gross margin 84.09%
FCF margin 37.03%
Quality
2 /100
Poor ROA 7.47%
ROIC 7.38%
Asset turnover 0.16x
Debt
69 /100
Low Int. coverage -2.15x
Debt/Equity 0.22x
Current ratio 2.43x
Stability
50 /100
Moderate EPS volatility 22.60%
Beta 0.81x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o MESO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Silviu Itescu
Employees
108
Headquarters
Melbourne
Prihajajoči dogodki
04 MAR.
Earnings
Upcoming earnings report